RegJoint
- VendorArgomedical
RegJoint
- VendorArgomedical
SKU: SMAGRG0001
€500,00
-
Guaranteed safe and secure.
- Shipped today? Order within:
- Free shipping on orders over €150.00
SKU: SMAGRG0001
€500,00
Guaranteed safe and secure.
RegJoint™ is an advanced, bioresorbable implant specifically designed for painful small joints in the hand and foot. Made from highly porous polylactide (PLDLA), it is naturally absorbed by the body while supporting the formation of a new functional joint.
The Institute of Biomaterials at Tampere University of Technology, in collaboration with Bionx (later Linvatec Biomaterials Ltd., Finland, now Scaffdex/Finland), developed this biodegradable spacer from poly-L/D-lactide copolymer with an L/D-monomer ratio of 96/4 (PLDLA).
The material is spun into four-ply very thin threads, which are then knitted into a tube. This tube is then rolled up like a fire hose and processed into a cushion of various sizes and thicknesses.
| Available Sizes | 9 sizes in 2 mm increments (8-24 mm diameter) |
|---|---|
| Thickness | 3.6-4.5 mm |
| Pore Size | 100-400 µm |
| Material | Poly-L/D-lactide copolymer (PLDLA) |
| CE Certification | Since November 2011 |
Natural degradation in the body into water and carbon dioxide within 2-3 years.
Promotes the formation of new, functional tissue that serves as a joint.
Maintains joint function and natural limb length after surgery.
Proven significant reduction in pain for patients.
Can be performed on an outpatient or inpatient basis.
Uncomplicated and low-complication surgical method, confirmed by over 10 years of clinical experience.
RegJoint™ uses the body's natural healing process in an innovative way. After implantation, the porous structure serves as a scaffold for ingrowing tissue. After about three months, flexible connective tissue forms, serving as a functional joint and enabling natural mobility.
In vitro studies show that the PLDLA used has a structural resorption of 50% after 13 weeks, which is long enough for the ingrowth of the body's own tissue. The implant is simultaneously slowly resorbed by the body and completely broken down into water and carbon dioxide within 2-3 years, leaving no residue.
Established in resection interposition arthroplasty of the MTP 1 for osteoarthritis and rheumatoid arthritis. Statistical analysis of the 5-year follow-up showed significant advantages regarding pain, function, and AOFAS score.
For the treatment of osteonecrosis of the metatarsal head, first described in 1914 by US surgeon Freiberg. The disease occurs in 60-88% of cases in metatarsal 2 and is more common in females.
Good experience as an alternative to conventional fat interposition in the treatment of calcanonavicular coalition.
The first human implantation took place in Finland in 1997 without implant-related complications. A comprehensive multicenter study from 2001, which led to the CE certification of the product, demonstrates the significant advantages of RegJoint™ over conventional surgical methods in terms of pain reduction and functionality.
In patients with simultaneous treatment of metatarsals 1-5, a significant advantage of RegJoint® was demonstrated for the parameters pain (VAS), function (VAS), and AOFAS score after 5 years. Long-term observations over more than 10 years confirm the sustainable results and the significant improvement in quality of life after the procedure.
For optimal results, the porous structure of the implant must be carefully preserved during surgery. The specific nature of the material is crucial for successful tissue integration and the formation of the functional pseudo-joint.